Engineered B Cells as Therapeutic Platforms: Engineering Strategies, Preclinical Evidence, and Translational Challenges
Clinical & Molecular Biomedicine · 30.09.2026 · 1 (2) · 8
DOI: 10.53295/cmb.v1.i2.100009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Molecular Biomedicine, online erschienen am 30.09.2026. Verfasst von Yashfeen Munib Siddiqui und 1 weiteren Autor:innen. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
B cells combine antigen-specific recognition, antigen presentation, antibody secretion, and differentiation into long-lived plasma cells, making them attractive candidates for therapeutic engineering. Advances in genome editing and synthetic biology have enabled therapeutic protein and antibody production, programmable antigen recognition, and controlled cellular responses. This review examines the biological basis of engineered B cell platforms, major genetic and functional engineering strategies, therapeutic applications, preclinical evidence, and barriers to translation. Preclinical studies have demonstrated sustained production of therapeutic proteins and antibodies, antibody-mediated antitumor effects, and antigen presentation that can activate antigen-specific T cell responses. These findings support using engineered B cells as durable sources of therapeutic molecules and as active participants in immune regulation. However, the field remains predominantly preclinical. Reliable control of editing efficiency, differentiation, persistence, therapeutic output, manufacturing, genomic safety, and long-term function will be required before clinical use. Engineered B cells therefore represent a promising therapeutic platform, but their efficacy and safety in patients remain to be established. Keywords: Engineered B cells; genome engineering; synthetic biology; therapeutic protein production; antigen recognition
Zitieren
APA
Siddiqui, Y. M., & Khan, F. (2026). Engineered B Cells as Therapeutic Platforms: Engineering Strategies, Preclinical Evidence, and Translational Challenges. Clinical & Molecular Biomedicine, 1(2), 8. https://doi.org/10.53295/cmb.v1.i2.100009
Vancouver
Siddiqui YM, Khan F. Engineered B Cells as Therapeutic Platforms: Engineering Strategies, Preclinical Evidence, and Translational Challenges. Clinical & Molecular Biomedicine. 2026;1(2):8. doi:10.53295/cmb.v1.i2.100009
BibTeX
@article{Siddiqui2026,
author = {Siddiqui, Yashfeen Munib and Khan, Fazlurrahman},
title = {Engineered B Cells as Therapeutic Platforms: Engineering Strategies, Preclinical Evidence, and Translational Challenges},
journal = {Clinical & Molecular Biomedicine},
year = {2026},
volume = {1},
number = {2},
pages = {8},
doi = {10.53295/cmb.v1.i2.100009}
}
EUVIMED